Measuring how allopurinol is removed by peritoneal dialysis

Not Applicable

Completed

• Conditions: Renal and Urogenital - Kidney disease; Musculoskeletal - Other muscular and skeletal disorders; Gout; Chronic kidney disease

• Registration Number: ACTRN12620001005943
• Lead Sponsor: Professor Robert Walker

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-06
• Study Completion: 2022-11-30
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

A peritoneal dialysis patient with a prior diagnosis of gout receiving allopurinol therapy will be eligible for inclusion.

Exclusion Criteria

Participants who are unable or unwilling to give written informed consent, who are taking concurrent losartan, probenecid, or benzbromarone, who are undergoing treatment for peritonitis, or who use an automated peritoneal dialysis set up will be excluded.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Observed change in oxypurinol plasma concentration over 24 hours[Plasma concentrations of oxypurinol observed at the following times after the patients usual morning dose of allopurinol; 0, 2, 4, 6, 8, 10 and 24 hours post-dose. ];Dialysate oxypurinol cumulative amount excreted over the 24h study peroid. [Dialysate oxypurinol concentrations (and volume) will be measured at the time of each dialysate bag exchange at 4, 8, 12 and 24 (4 bags over 24 hours). ];Urine oxypurinol cumulative amount excreted over the 24h study peroid. [Urine will be collected continuously over the 24 hour study period (volume and oxypurinol concentrations are measured at 3hr, 6hr and 24 hr)]

Secondary Outcome Measures

Name	Time	Method
Dialysate urate cumulative amount excreted over the 24h study peroid. [Dialysate urate concentrations (and volume) will be measured at the time of each dialysate bag exchange at 4, 8, 12 and 24 (4 bags over 24 hours). ];Urine urate cumulative amount excreted over the 24h study peroid. [Urine will be collected continuously over the 24 hour study period (volume and urate concentrations are measured at 3hr, 6hr and 24 hr)];Observed change in urate plasma concentration over 24 hours[Plasma concentrations of urate observed at the following times after the patients usual morning dose of allopurinol; 0, 2, 4, 6, 8, 10 and 24 hours post-dose. ]